Clinical Trials Logo

Hodgkin Disease Recurrent clinical trials

View clinical trials related to Hodgkin Disease Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT05352828 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

ACTION
Start date: July 25, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.

NCT ID: NCT04268706 Active, not recruiting - Clinical trials for Hodgkin Lymphoma, Adult

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.